Literature DB >> 36149567

Immune Response to SARS-CoV-2 Infections in Children with Secondary Immunodeficiencies.

Karolina Kuczborska1, Ewelina Krzemińska2, Piotr Buda2, Edyta Heropolitańska-Pliszka3, Barbara Piątosa4, Janusz Książyk2.   

Abstract

BACKGROUND AND
PURPOSE: It is a matter of research, whether children with immunodeficiencies are able to generate an effective immune response to prevent SARS-CoV-2 reinfection. This study aimed to evaluate and compare the seroconversion rates and changes of lymphocyte subsets during COVID-19 in immunocompetent children and those with secondary immunodeficiencies.
METHODS: In 55 children - 28 immunocompromised and 27 immunocompetent - hospitalized with confirmed SARS-CoV-2 infection, the level of IgG antibodies against the Spike protein was determined on two to three occasions. In those children from the study group whose immunosuppressive treatment did not alter during the study (n = 13) and in selected children from the control group (n = 11), flow cytometric evaluation of lymphocyte subsets was performed twice - 2 weeks and 3 months post-infection.
RESULTS: Seroconversion reached 96.3% in both studied groups; however, the immunocompromised cohort achieved lower titers of detectable anti-S antibodies. There was no correlation between seroconversion or titers of antibodies and the total number of lymphocytes or their subsets. In the immunocompetent cohort, we reported a significant decrease in NK cells during the infection. In this group and the entire study population, a positive correlation was noticed between the CD4 + /CD8 + T cell ratio and the severity of COVID-19 pneumonia.
CONCLUSIONS: Children with secondary immunodeficiencies seroconvert in equal percentages but with a significantly lower titer of anti-S antibodies compared to their immunocompetent peers. The lower number of NK cells in the immunocompetent cohort may result from their participation in antiviral immunity, whereas reduced CD4 + /CD8 + T cell ratios among immunocompromised children may be a protective factor against a severe COVID-19.
© 2022. The Author(s).

Entities:  

Keywords:  COVID-19; Cancer; Children; Immunodeficiency; Kidney transplantation; Lymphocyte subsets; SARS-CoV-2; Serology

Year:  2022        PMID: 36149567     DOI: 10.1007/s10875-022-01365-8

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  5 in total

1.  COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential.

Authors:  Yujie Jiang; Xin Wei; Jingjing Guan; Shuang Qin; Zhongyong Wang; Hong Lu; Jingjing Qian; Lianfeng Wu; Yingxiao Chen; Yanfan Chen; Xiangyang Lin
Journal:  Clin Immunol       Date:  2020-06-20       Impact factor: 3.969

Review 2.  Humoral Responses and Serological Assays in SARS-CoV-2 Infections.

Authors:  Yannick Galipeau; Matthew Greig; George Liu; Matt Driedger; Marc-André Langlois
Journal:  Front Immunol       Date:  2020-12-18       Impact factor: 7.561

3.  Effects of Coronavirus Disease 2019 (COVID-19) on Peripheral Blood Lymphocytes and Their Subsets in Children: Imbalanced CD4+/CD8+ T Cell Ratio and Disease Severity.

Authors:  Shima Mahmoudi; Bahareh Yaghmaei; Meisam Sharifzadeh Ekbatani; Babak Pourakbari; Amene Navaeian; Nima Parvaneh; Mohammad Taghi Haghi Ashtiani; Setareh Mamishi
Journal:  Front Pediatr       Date:  2021-04-14       Impact factor: 3.418

Review 4.  Antibody Responses in COVID-19: A Review.

Authors:  Mateo Chvatal-Medina; Yorjagis Mendez-Cortina; Pablo J Patiño; Paula A Velilla; Maria T Rugeles
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

5.  Clinical Course of COVID-19 Disease in Children Treated With Neoplastic Diseases in Hungary.

Authors:  Judit Müller; Dóra Szűcs-Farkas; István Szegedi; Monika Csóka; Miklós Garami; Lilla Györgyi Tiszlavicz; Péter Hauser; Gergely Kriván; Krisztina Csanádi; Gábor Ottóffy; Béla Nagy; Csongor Kiss; Gábor Kovács
Journal:  Pathol Oncol Res       Date:  2022-03-31       Impact factor: 3.201

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.